Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against a Genital Challenge and Re-Challenge

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 May 3

PMID 33936096

Citations 7

Authors

Rajnish Sahu

Saurabh Dixit

Richa Verma

Skyla A Duncan

Lula Smith

Guillermo H Giambartolomei

Shree R Singh

Vida A Dennis

Affiliations

Soon will be listed here.

Abstract

Recently we reported the immune-potentiating capacity of a nanovaccine (PLGA-rMOMP) comprising rMOMP (recombinant major outer membrane protein) encapsulated in extended-releasing PLGA [poly (D, L-lactide-co-glycolide) (85:15)] nanoparticles. Here we hypothesized that PLGA-rMOMP would bolster immune-effector mechanisms to confer protective efficacy in mice against a genital challenge and re-challenge. Female BALB/c mice received three immunizations, either subcutaneously (SC) or intranasally (IN), before receiving an intravaginal challenge with on day 49 and a re-challenge on day 170. Both the SC and IN immunization routes protected mice against genital challenge with enhanced protection after a re-challenge, especially in the SC mice. The nanovaccine induced robust antigen-specific Th1 (IFN-γ, IL-2) and IL-17 cytokines plus CD4 proliferating T-cells and memory (CD44 CD62L) and effector (CD44 CD62L) phenotypes in immunized mice. Parallel induction of antigen-specific systemic and mucosal Th1 (IgG2a, IgG2b), Th2 (IgG1), and IgA antibodies were also noted. Importantly, immunized mice produced highly functional Th1 avidity and serum antibodies that neutralized infectivity of McCoy fibroblasts that correlated with their respective protection levels. The SC, rather than the IN immunization route, triggered higher cellular and humoral immune effectors that improved mice protection against genital We report for the first time that the extended-releasing PLGA 85:15 encapsulated rMOMP nanovaccine confers protective immunity in mice against genital and advances the potential towards acquiring a nano-based vaccine.

Citing Articles

Cell-Free Screening, Production and Animal Testing of a STI-Related Chlamydial Major Outer Membrane Protein Supported in Nanolipoproteins.

Mohagheghi M, Abisoye-Ogunniyan A, Evans A, Peterson A, Bude G, Hoang-Phou S Vaccines (Basel). 2024; 12(11).

PMID: 39591149 PMC: 11598365. DOI: 10.3390/vaccines12111246.

Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.

Sahu R, Verma R, Egbo T, Giambartolomei G, Singh S, Dennis V Pathog Dis. 2024; 82.

PMID: 38862192 PMC: 11186516. DOI: 10.1093/femspd/ftae004.

PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice.

Yilma A, Sahu R, Subbarayan P, Villinger F, Coats M, Singh S Int J Nanomedicine. 2024; 19:1287-1301.

PMID: 38348174 PMC: 10860865. DOI: 10.2147/IJN.S432970.

Efficacy of Pgp3 vaccination for urogenital tract infection depends on its native conformation.

Peng B, Zhong S, Hua Y, Luo Q, Dong W, Wang C Front Immunol. 2022; 13:1018774.

PMID: 36466885 PMC: 9709265. DOI: 10.3389/fimmu.2022.1018774.

Immune modulating nanoparticles for the treatment of ocular diseases.

Fang L, Liu J, Liu Z, Zhou H J Nanobiotechnology. 2022; 20(1):496.

PMID: 36424630 PMC: 9694601. DOI: 10.1186/s12951-022-01658-5.

References

Khademi F, Yousefi A, Derakhshan M, Najafi A, Tafaghodi M . Enhancing immunogenicity of novel multistage subunit vaccine of using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration. Iran J Basic Med Sci. 2019; 22(8):893-900. PMC: 6760476. DOI: 10.22038/ijbms.2019.33962.8079. View

Yu H, Karunakaran K, Kelly I, Shen C, Jiang X, Foster L . Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunol. 2011; 186(6):3615-21. PMC: 3072838. DOI: 10.4049/jimmunol.1002952. View

Kemp J, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S . Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine. 2002; 20(7-8):1089-98. DOI: 10.1016/s0264-410x(01)00444-3. View

Farris C, Morrison S, Morrison R . CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010; 78(10):4374-83. PMC: 2950360. DOI: 10.1128/IAI.00622-10. View

Gutjahr A, Phelip C, Coolen A, Monge C, Boisgard A, Paul S . Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines (Basel). 2016; 4(4). PMC: 5192354. DOI: 10.3390/vaccines4040034. View

Moore T, Ananaba G, Bolier J, Bowers S, Belay T, Eko F . Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002; 105(2):213-21. PMC: 1782645. DOI: 10.1046/j.0019-2805.2001.01354.x. View

Moore-Connors J, Fraser R, Halperin S, Wang J . CD4⁺CD25⁺Foxp3⁺ regulatory T cells promote Th17 responses and genital tract inflammation upon intracellular Chlamydia muridarum infection. J Immunol. 2013; 191(6):3430-9. DOI: 10.4049/jimmunol.1301136. View

Urbanavicius D, Alvarez T, Such G, Johnston A, Mintern J . The potential of nanoparticle vaccines as a treatment for cancer. Mol Immunol. 2018; 98:2-7. DOI: 10.1016/j.molimm.2017.12.022. View

de la Maza L, Zhong G, Brunham R . Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol. 2017; 24(4). PMC: 5382834. DOI: 10.1128/CVI.00543-16. View

10.

Silva A, Soema P, Slutter B, Ossendorp F, Jiskoot W . PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016; 12(4):1056-69. PMC: 4962933. DOI: 10.1080/21645515.2015.1117714. View

11.

Hafner L, Wilson D, Timms P . Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine. 2013; 32(14):1563-71. DOI: 10.1016/j.vaccine.2013.08.020. View

12.

Stary G, Olive A, Radovic-Moreno A, Gondek D, Alvarez D, Basto P . VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015; 348(6241):aaa8205. PMC: 4605428. DOI: 10.1126/science.aaa8205. View

13.

Su H, Caldwell H . Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis. Vaccine. 1993; 11(11):1159-66. DOI: 10.1016/0264-410x(93)90080-h. View

14.

Sahu R, Dixit S, Verma R, Duncan S, Coats M, Giambartolomei G . A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4 effector (CD44 CD62L) and memory (CD44 CD62L) T-cells in immunized mice. Nanomedicine. 2020; 29:102257. PMC: 10198673. DOI: 10.1016/j.nano.2020.102257. View

15.

Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D . Nanoparticle-Based Vaccines Against Respiratory Viruses. Front Immunol. 2019; 10:22. PMC: 6353795. DOI: 10.3389/fimmu.2019.00022. View

16.

Li Y, Wei C, Xu H, Jia J, Wei Z, Guo R . The Immunoregulation of Th17 in Host against Intracellular Bacterial Infection. Mediators Inflamm. 2018; 2018:6587296. PMC: 5884031. DOI: 10.1155/2018/6587296. View

17.

Tam H, Melo M, Kang M, Pelet J, Ruda V, Foley M . Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A. 2016; 113(43):E6639-E6648. PMC: 5086995. DOI: 10.1073/pnas.1606050113. View

18.

Alam M, Arifuzzaman M, Ahmad S, Hosen M, Rahman M, Rashu R . Study of avidity of antigen-specific antibody as a means of understanding development of long-term immunological memory after Vibrio cholerae O1 infection. Clin Vaccine Immunol. 2012; 20(1):17-23. PMC: 3535784. DOI: 10.1128/CVI.00521-12. View

19.

Lutsiak M, Kwon G, Samuel J . Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol. 2006; 58(6):739-47. DOI: 10.1211/jpp.58.6.0004. View

20.

Yu H, Lin H, Xie L, Tang L, Chen J, Zhou Z . Chlamydia muridarum Induces Pathology in the Female Upper Genital Tract via Distinct Mechanisms. Infect Immun. 2019; 87(8). PMC: 6652751. DOI: 10.1128/IAI.00145-19. View